3 Life Sciences Technology Firm, Contract Development Specialist and Diagnostics Chain Stocks With a Strong Future Roadmap: Indegene, Anthem Biosciences and Dr. Lal PathLabs
- October 29, 2026
- Posted by: Ankit Jaiswal
- Category: Best Stocks
Indegene, Anthem Biosciences and Dr. Lal PathLabs: ROE of 12.8% to 20.1% and FY22 to FY26 revenue CAGR of 7.6% to 20.7%. Prices as of 28 Oct 2026.
Quick Answer
The three life sciences, contract research and diagnostics to watch are Indegene, Anthem Biosciences and Dr. Lal PathLabs. Their return on equity ranges from 12.8% to 20.1%, and their revenue compound annual growth from FY22 to FY26 ranges from 7.6% to 20.7%. Dr. Lal PathLabs has the highest return on equity at 20.1%, while Indegene has the fastest revenue growth at 20.7% a year. Prices are based on the 28 October 2026 close, and this article is educational, not investment advice.
Life sciences, contract research and diagnostics give investors a way to track businesses that sit close to everyday demand in India. Indegene, Anthem Biosciences and Dr. Lal PathLabs cover a life sciences technology firm, a contract development specialist and a diagnostics chain.
This list covers three life sciences, contract research and diagnostics with complete current figures: Indegene, Anthem Biosciences and Dr. Lal PathLabs. Every figure comes from the latest reported financials and the 28 October 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Life Sciences, Contract Research and Diagnostics?
Life sciences, contract research and diagnostics are listed healthcare companies that provide digital, medical and commercial services to drug and device makers, develop and manufacture molecules for global pharma clients and run laboratories and collection centres for pathology tests. Their earnings depend on client programmes, project volumes and test demand.
Life Sciences, Contract Research and Diagnostics at a Glance
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE (%) | D/E |
|---|---|---|---|---|---|---|
| Indegene | 598.95 | 14,454 | 36.0 | 59.2 | 12.8 | 0.05 |
| Anthem Biosciences | 832.15 | 45,546 | 79.1 | 36.0 | 19.4 | 0.02 |
| Dr. Lal PathLabs | 1,922.3 | 30,949 | 56.6 | 59.6 | 20.1 | 0.08 |
On valuation, Indegene and Dr. Lal PathLabs trade at a P/E below the industry P/E, while Anthem Biosciences trades above it, which reflects the growth the market already expects. Readers comparing life sciences, contract research and diagnostics should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.
Why Do Life Sciences, Contract Research and Diagnostics Have a Strong Roadmap in India?
Life sciences, contract research and diagnostics have a strong roadmap in India because rising outsourcing by global drug makers, growing demand for contract development and manufacturing and wider awareness of preventive health tests keep widening the market for these healthcare companies.
- Pharma outsourcing. Drug makers hand more work to specialists.
- Contract development. Global clients need molecules developed and made.
- Preventive tests. Households seek regular health checks.
Why Indegene Features Among These Life Sciences, Contract Research and Diagnostics
Among the life sciences, contract research and diagnostics on this list, Indegene is a Bengaluru-based healthcare technology and services company that helps biopharma and medical technology firms with commercial, medical and regulatory work using data and technology.
The company has a return on equity of 12.8%, a debt to equity ratio of 0.05 and a market capitalisation of Rs 14,454 crore. The stock trades at a P/E of 36.0, below the industry P/E of 59.2.
Revenue rose from Rs 1,690 crore in FY22 to Rs 3,582 crore in FY26, a compound annual growth rate of 20.7%. Net profit grew from Rs 163 crore in FY22 to Rs 401 crore in FY26, which works out to a compound annual growth rate of 25.3%. In the June 2026 quarter, revenue grew 39.5% year on year to Rs 1,092 crore.
Roadmap: The company is widening its digital and artificial intelligence services for life sciences clients and adding new customers across drug and device makers. Multi-year contracts with global clients support recurring revenue.
What to watch: Monitor client additions, platform adoption and growth in artificial intelligence services.
Why Anthem Biosciences Features Among These Life Sciences, Contract Research and Diagnostics
Among the pharma services and pathology shares on this list, Anthem Biosciences is a research-driven contract development and manufacturing organisation that serves global pharma and biotech customers with discovery, development and manufacturing services.
Revenue rose from Rs 1,280 crore in FY22 to Rs 2,280 crore in FY26, a compound annual growth rate of 15.5%. Net profit grew from Rs 406 crore in FY22 to Rs 592 crore in FY26, which works out to a compound annual growth rate of 9.9%.
The company has a return on equity of 19.4%, a debt to equity ratio of 0.02 and a market capitalisation of Rs 45,546 crore. The stock trades at a P/E of 79.1, above the industry P/E of 36.0.
Roadmap: The company offers an integrated platform from discovery to commercial manufacturing, which makes it a partner for innovator clients. Its biologics, peptides and small-molecule services give it several routes to growth.
What to watch: Monitor the order pipeline from global customers and the ramp-up of newer manufacturing capacity.
Why Dr. Lal PathLabs Features Among These Life Sciences, Contract Research and Diagnostics
Among the three companies on this list, Dr. Lal PathLabs is one of India’s best-known diagnostics companies, operating a national reference laboratory with a hub-and-spoke network of labs, patient service centres and collection points.
In the June 2026 quarter, revenue grew 18.9% year on year to Rs 830 crore, while net profit rose 27.2% to Rs 170 crore. Revenue rose from Rs 2,140 crore in FY22 to Rs 2,864 crore in FY26, a compound annual growth rate of 7.6%.
Net profit grew from Rs 350 crore in FY22 to Rs 510 crore in FY26, which works out to a compound annual growth rate of 9.8%. The company has a return on equity of 20.1%, a debt to equity ratio of 0.08 and a market capitalisation of Rs 30,949 crore. The stock trades at a P/E of 56.6, below the industry P/E of 59.6.
Roadmap: Its asset-light collection network lets the company enter new towns without heavy capital spending. Growth levers include test menu expansion in oncology and genetics, wellness packages and deeper reach in North and East India through franchise and direct collection centres.
What to watch: Follow test volumes per patient and the balance between routine and specialised tests.
Indegene vs Anthem Biosciences vs Dr. Lal PathLabs on Key Financials
The table below sets the three life sciences, contract research and diagnostics side by side on revenue, profit and margin, using reported figures.
| Company | FY22 Revenue (Rs Cr) | FY26 Revenue (Rs Cr) | Revenue CAGR (FY22-FY26) | FY26 Net Profit (Rs Cr) | FY26 Net Margin |
|---|---|---|---|---|---|
| Indegene | 1,690 | 3,582 | 20.7% | 401 | 11.2% |
| Anthem Biosciences | 1,280 | 2,280 | 15.5% | 592 | 26.0% |
| Dr. Lal PathLabs | 2,140 | 2,864 | 7.6% | 510 | 17.8% |
Dr. Lal PathLabs posts the highest return on equity in this group at 20.1%. Indegene combines the largest FY26 revenue at Rs 3,582 crore with the fastest revenue growth, a 20.7% compound annual rate. A useful habit with life sciences, contract research and diagnostics is to check each new quarterly result against the capacity plans the company described earlier.
Key Risks to Check Before Investing in Life Sciences, Contract Research and Diagnostics
Every theme carries risks that deserve a check before any decision. For these life sciences, contract research and diagnostics, the main points are: Long-term pharma services and pathology shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.
- Regulatory approvals. Plant inspections and approvals can affect supplies.
- Currency moves. Export earnings move with the rupee.
- Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.
Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.
Use the Univest Stock Screener to filter life sciences, contract research and diagnostics by market capitalisation, P/E, ROE and growth, and build your own shortlist.
Final Thoughts on Life Sciences, Contract Research and Diagnostics
Life sciences, contract research and diagnostics work best when investors track growth, valuation and return on equity side by side. Indegene, Anthem Biosciences and Dr. Lal PathLabs each have a clear plan to grow. Based on the 28 October 2026 close, Indegene trades at Rs 598.95, Anthem Biosciences at Rs 832.15 and Dr. Lal PathLabs at Rs 1,922.3. Valuation matters as much as growth, so compare each company’s P/E with its industry P/E before adding any of these life sciences, contract research and diagnostics to a watchlist.
Download the Univest iOS App or Univest Android App to track life sciences, contract research and diagnostics, set price alerts and get research-backed stock ideas.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
What are life sciences, contract research and diagnostics?
Ans. Life sciences, contract research and diagnostics are listed healthcare companies that provide digital, medical and commercial services to drug and device makers, develop and manufacture molecules for global pharma clients and run laboratories and collection centres for pathology tests. Their earnings depend on client programmes, project volumes and test demand. This list looks at three of them, Indegene, Anthem Biosciences and Dr. Lal PathLabs, using reported FY22 to FY26 financials and the 28 October 2026 closing prices.
Which life sciences, contract research and diagnostics are covered in this list?
Ans. This list covers Indegene, Anthem Biosciences and Dr. Lal PathLabs. Based on the 28 October 2026 close, Indegene traded at Rs 598.95, Anthem Biosciences at Rs 832.15 and Dr. Lal PathLabs at Rs 1,922.3. Their return on equity ranges from 12.8% to 20.1%, and their revenue compound annual growth from FY22 to FY26 ranges from 7.6% to 20.7%.
Why do life sciences, contract research and diagnostics have a strong future roadmap in India?
Ans. Life sciences, contract research and diagnostics have a strong roadmap in India because rising outsourcing by global drug makers, growing demand for contract development and manufacturing and wider awareness of preventive health tests keep widening the market for these healthcare companies. The main drivers are as follows. Pharma outsourcing. Drug makers hand more work to specialists. Contract development. Global clients need molecules developed and made. Preventive tests. Households seek regular health checks. Together these factors give the companies on this list a visible path for growth over the coming years.
How has Indegene performed financially?
Ans. Revenue rose from Rs 1,690 crore in FY22 to Rs 3,582 crore in FY26, a compound annual growth rate of 20.7%. Net profit grew from Rs 163 crore in FY22 to Rs 401 crore in FY26, which works out to a compound annual growth rate of 25.3%. In the June 2026 quarter, revenue grew 39.5% year on year to Rs 1,092 crore. The company has a return on equity of 12.8%, a debt to equity ratio of 0.05 and a market capitalisation of Rs 14,454 crore. The stock trades at a P/E of 36.0, below the industry P/E of 59.2. Looking ahead, the company is widening its digital and artificial intelligence services for life sciences clients and adding new customers across drug and device makers. Multi-year contracts with global clients support recurring revenue.
How has Anthem Biosciences performed financially?
Ans. Revenue rose from Rs 1,280 crore in FY22 to Rs 2,280 crore in FY26, a compound annual growth rate of 15.5%. Net profit grew from Rs 406 crore in FY22 to Rs 592 crore in FY26, which works out to a compound annual growth rate of 9.9%. The company has a return on equity of 19.4%, a debt to equity ratio of 0.02 and a market capitalisation of Rs 45,546 crore. The stock trades at a P/E of 79.1, above the industry P/E of 36.0. Looking ahead, the company offers an integrated platform from discovery to commercial manufacturing, which makes it a partner for innovator clients. Its biologics, peptides and small-molecule services give it several routes to growth.
How has Dr. Lal PathLabs performed financially?
Ans. Revenue rose from Rs 2,140 crore in FY22 to Rs 2,864 crore in FY26, a compound annual growth rate of 7.6%. Net profit grew from Rs 350 crore in FY22 to Rs 510 crore in FY26, which works out to a compound annual growth rate of 9.8%. In the June 2026 quarter, revenue grew 18.9% year on year to Rs 830 crore, while net profit rose 27.2% to Rs 170 crore. The company has a return on equity of 20.1%, a debt to equity ratio of 0.08 and a market capitalisation of Rs 30,949 crore. The stock trades at a P/E of 56.6, below the industry P/E of 59.6. Looking ahead, its asset-light collection network lets the company enter new towns without heavy capital spending. Growth levers include test menu expansion in oncology and genetics, wellness packages and deeper reach in North and East India through franchise and direct collection centres.
What risks should investors check before buying life sciences, contract research and diagnostics?
Ans. Investors should check a few risks before buying life sciences, contract research and diagnostics. Regulatory approvals. Plant inspections and approvals can affect supplies. Currency moves. Export earnings move with the rupee. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.
Is this list of life sciences, contract research and diagnostics investment advice?
Ans. No. This article is educational and uses publicly available data as of the 28 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.
